Severe course of dilated cardiomyopathy associated with Duchenne muscular dystrophy (RCD code: III‑1A.3a)

Paweł Rubiś, Sylwia Wiśniowska‑Śmiałek, Lidia Tomkiewicz‑Pająk, Dawid Kudliński, Maria Olszowska, Piotr Podolec

Full Text:



Inherited neuromuscular disorders, such as dystrophin-related disorders are frequently associated with cardiac involvement, mainly with cardiomyopathies. Dystrophin-related disorders are caused by the mutation in the dystrophin gene on the X chromosome. Two types of dystrophin-related disorders, namely, Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) have been identified. DMD is a more severe form of muscular dystrophy. The cardinal symptoms of DMD are progressive skeletal muscle weakness and respiratory insufficiency due to the weakness of the respiratory muscle, which is the leading cause of premature death. Owing to the improvement in the general and respiratory care of DMD patients, associated cardiovascular abnormalities, mainly cardiomyopathies, are gradually becoming the main cause of comorbidity and mortality in these patients. We present a case of an 18 year-old male with DMD who developed heart failure with reduced ejection fraction due to dilated cardiomyopathy. Although the state-of-the-art treatment was initiated he eventually died from cardiopulmonary decompensation. Based on this case we provide thorough summary on the current knowledge on diagnosis and care of patients with DMD and heart failure.  JRCD 2014; 2 (1): 18–22


cardiomyopathy; Duchenne muscular dystrophy; myopathy; neuromuscular disorder; genetics


Eagle M, Baudouin SV, Chandler C, et al. Survival in Duchenne muscular dystrophy; improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscular Disord 2002; 12: 926–929.

Romfh A, McNally EM. Cardiac Assesment in Duchenne and Becker Muscular Dystrophies. Curr Heart Fail Rep. 2010; 7: 212–218.

Nigro G, Comi LI, Politano L, Bain RJ. The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. Int J Cardiol 1990; 26: 271–277

Strugalska-Cynowska MH. Dystrofia mięśniowa typu Duchenne’a. Warszawa 2003.

Lapidos KA, Kakkar R, McNally EM. The dystrophin glycoprotein complex: signaling strength and integrity for the sarcolemma. Circ Res 2004; 94: 1023–1031.

Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1 diagnosis and pharmacological and psychosocial management. Lancet Neurol 2010; 9: 77–93.

Puchalski MD, Williams MV, Askovich B, et al. Late gadolinium enhancement: precursors to cardiomyopathy in Duchenne muscular dystrophy? Int J Cardiovasc imaging 2009; 25: 57–63.

Silva MC, Meira ZM, Gurgel Giannetti J, et al. Myocardial delayed enhancement by magnetic resonance imaging in patients with muscular dystrophy, J AM Coll Cardiol 2007; 49: 1874–1879.

Wagner KR, Lechtzin N, Judge DP. Current treatment of adult Duchenne muscular dystrophy. Biochim biophys Acta 2007; 1772: 229–237.

Hahn A, Bach JR, Delaubier A, et al. Clinical implications of maximal respiratory pressure determinations for individuals with Duchenne muscular dystrophy. Arch Phys Med Rehabil 1997; 78: 1–6.

Duboc D, Meune C, Lerebours G, et al. Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy, J AM Coll Cardiol 2005; 48: 855–885.



  • There are currently no refbacks.
Journal of Rare Cardiovascular Diseases (JRCD)
John Paul II Hospital in Kraków, 80 Prądnicka Str., 31-202 Kraków, Poland
Phone: +48 (12) 614 33 99, +48 (12) 614 34 88 Fax: +48 (12) 614 34 88
Published by SoftQ sp. z o.o.
ul. Oleandry 2, 30-063 Kraków, Poland
Phone: +48 (12) 444 1650 Fax: +48 (12) 444 1659